Abstract | INTRODUCTION: METHODS: In this prospective 12-week open-label study, we evaluated the effectiveness of the addition of reboxetine to 141 outpatients diagnosed with major depressive disorder, according to DSM-IV-TR criteria, who were partial responders or non-responders over a period of 6 weeks, to previous treatment in monotherapy with SSRI. Evaluation of antidepressant efficacy was carried out through the application of the Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impressions-Global Improvement Scale (CGI-I). Data were analyzed on an intent-to-treat basis, using the last-observation-carried-forward method. RESULTS: Mean score on the HDRS at baseline was 26.24+/-7.21, falling to 13.96+/-8.00 in week 12 (mean decrease of 46.79%; p<0.0001) The percentages of responders (HDRS total score > or =50%) and patients considered as benefiting from complete remission (HDRS score < or =10) at 12 weeks were 50.4% and 34.5%, respectively. By the end of the treatment, a mean decrease in CGI-I score of 1.88 points was obtained (41.14% of reduction; p<0.0001), and 77% of the patients were evaluated as improved (CGI-I score <4). Nervousness was the adverse effect most frequently reported (5.21%), followed by dryness of mouth (4.38%), and insomnia (3.56%). CONCLUSION: The results of this study suggest that the combination strategy with reboxetine appears to be a potentially useful tool in cases of SSRI-resistant depression.
|
Authors | F López-Muñoz, C Alamo, G Rubio, P García-García, A Pardo |
Journal | Pharmacopsychiatry
(Pharmacopsychiatry)
Vol. 40
Issue 1
Pg. 14-9
(Jan 2007)
ISSN: 0176-3679 [Print] Germany |
PMID | 17327955
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antidepressive Agents
- Morpholines
- Serotonin Uptake Inhibitors
- Reboxetine
|
Topics |
- Adult
- Antidepressive Agents
(therapeutic use)
- Depressive Disorder, Major
(drug therapy, psychology)
- Drug Resistance
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Morpholines
(therapeutic use)
- Prospective Studies
- Psychiatric Status Rating Scales
- Reboxetine
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
|